Argenx stock hits historic record at €913 in trading session
The Dutch immunology group touches a new absolute peak during the session, surpassing the previous record established two days earlier. This spike occurs in a serene market context, as the stock chains catalysts over several weeks.
A historic record at €913 after breaking through the €907.4 resistance level
The argenx stock touched €913.00 during the session, beating its previous historic record of €911.40 reached on August 26. The stock thus broke above its €907.4 resistance level during the session, before slightly retreating to €906.20, representing a marginal decline of 0.13% compared to the previous close. Over the past three months, the gain reaches nearly 28%, and the one-year performance exceeds 49%.
These gains are part of a dynamic driven by several recent developments: the positive phase 3 trial in autoimmune myositis, announced on August 17, has broadened the potential of efgartigimod beyond already commercialized indications. The RSI at 68 approaches the overbought zone without entering it decisively, while the price evolves well above its three moving averages: the 20-day MA at €808.04 (spread of over 12%), the 50-day MA at €792.12 (spread of over 14%) and the 200-day MA at €725.04 (spread of nearly 25%). This configuration signals a particularly pronounced underlying bullish trend.
Forte Biosciences acquisition finalized, anti-CD122 antibody integrated into portfolio
On the corporate front, the acquisition of Forte Biosciences at 77 dollars per share was finalized on August 27. This operation, whose takeover bid was launched in early August, brings argenx FB102, an anti-CD122 antibody already with clinical data in vitiligo and celiac disease. It thus expands the group's pipeline, whose flagship product VYVGART and its subcutaneous formulation VYVGART Hytrulo are already commercialized in generalized myasthenia gravis and chronic inflammatory demyelinating polyradiculoneuropathy.
During the publication of the second quarter 2026 results (July 1, 2026), the group had highlighted important registration study readouts expected in the second half, which maintains attention on the upcoming clinical calendar. On valuation, according to the consensus of surveyed analysts, the stock trades at approximately 37 times expected earnings for the current fiscal year and 29.5 times those of the following fiscal year, reflecting the high expectations associated with this growth story. The VIX at 14.48 reflects a globally pacified market, in which the CAC 40 gains nearly 1% during the session.
